Drug Patents owned by Amgen Inc
1. List of Corlanor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 22, 2026 |
| Pediatric Exclusivity (PED) | Oct 22, 2026 |
Drugs and Companies using IVABRADINE ingredient
Market Authorisation Date: 22 April, 2019
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: SOLUTION;ORAL
CORLANOR family patents
6
United States
4
France
2
Colombia
2
Ecuador
2
AP
2
Australia
2
EA
2
Croatia
2
Korea, Republic of
2
Canada
2
New Zealand
2
Denmark
2
Spain
2
Uruguay
2
Peru
2
Saudi Arabia
2
Malaysia
2
Costa Rica
2
Austria
2
ME
2
Cyprus
2
Singapore
2
Jordan
2
Portugal
2
Ukraine
2
Poland
2
Japan
2
Morocco
2
Norway
2
Hong Kong
2
Slovenia
2
Guatemala
2
Georgia
2
Argentina
2
RS
2
China
2
Brazil
2
South Africa
2
Cuba
2
Germany
2
Taiwan
2
European Union
2. List of Corlanor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7361649 (Pediatric) | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7879842 (Pediatric) | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7361650 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7867996 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(4 years from now) | |
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2015
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: TABLET;ORAL
CORLANOR family patents
6
United States
4
France
2
Colombia
2
Ecuador
2
AP
2
Australia
2
EA
2
Croatia
2
Korea, Republic of
2
Canada
2
New Zealand
2
Denmark
2
Spain
2
Uruguay
2
Peru
2
Saudi Arabia
2
Malaysia
2
Costa Rica
2
Austria
2
ME
2
Cyprus
2
Singapore
2
Jordan
2
Portugal
2
Ukraine
2
Poland
2
Japan
2
Morocco
2
Norway
2
Hong Kong
2
Slovenia
2
Guatemala
2
Georgia
2
Argentina
2
RS
2
China
2
Brazil
2
South Africa
2
Cuba
2
Germany
2
Taiwan
2
European Union
3. List of Lumakras drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(14 years from now) | |
| US11236091 | AMGEN INC | Solid state forms |
May, 2040
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Aug, 2040
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
| Orphan Drug Exclusivity (ODE) | May 28, 2028 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 2025-05-28
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...
Dosage: TABLET;ORAL
LUMAKRAS family patents
14
United States
11
Argentina
7
Japan
5
European Union
4
Australia
4
Israel
3
Korea, Republic of
3
Canada
3
Chile
3
Singapore
3
China
3
Taiwan
2
Colombia
2
EA
2
Uruguay
2
Peru
2
Costa Rica
2
Morocco
2
Brazil
1
Croatia
1
Denmark
1
Spain
1
Saudi Arabia
1
Jordan
1
Portugal
1
Philippines
1
Poland
1
Slovenia
1
Mexico
1
RS
1
Hungary
1
Lithuania
4. List of Otezla drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(6 months from now) | |
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 months ago) | |
| US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(2 months ago) | |
| US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 months ago) | |
| US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(2 months ago) | |
| US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(2 months ago) | |
| US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(2 months ago) | |
| US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 months ago) | |
| US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(10 years from now) | |
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jul 19, 2026 |
| M (M) | Apr 10, 2023 |
| New Indication (I) | Dec 20, 2024 |
Drugs and Companies using APREMILAST ingredient
Market Authorisation Date: 21 March, 2014
Treatment: Use of otezla (apremilast) for the treatment of psoriatic arthritis; Use of otezla (apremilast) for the treatment of psoriasis; Treatment of adult patients with oral ulcers associated with behcet's di...
Dosage: TABLET;ORAL
OTEZLA family patents
33
United States
10
European Union
8
Spain
7
Korea, Republic of
6
Denmark
6
Portugal
5
Slovenia
5
Hungary
4
Cyprus
4
Japan
4
Hong Kong
4
China
3
Mexico
2
Australia
2
Israel
2
Canada
2
New Zealand
1
Luxembourg
1
Netherlands
1
Austria
1
Germany
1
Brazil
1
South Africa
1
Belgium
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic